Ondine Accelerates its MRSA Nasal Decolonization Program Following reports of complete eradication in 5 patients without use of Antibiotics

    VANCOUVER, Nov. 12 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP) today announced plans to accelerate its MRSA nasal decolonization
program, following reports of 5 consecutive cases of complete eradication in
patients colonized with the potentially lethal methicillin-resistant
Staphylococcus aureus (MRSA) by an independent clinician. The company intends
to initiate a clinical trial in the first quarter of 2008 in order to test
next generation products which optimize its nasal decolonization product for
ease of clinical use, market acceptance and which support future regulatory
submissions for nares decolonization of MRSA.
    Ondine has received five case study reports demonstrating full
eradication of MRSA in the anterior nares (lower nasal passage) without the
use of antibiotics. The studies were carried out by an independent clinician,
Dr. Herbert Friede, in Herborn, Germany using Ondine's photodisinfection
system for nares decolonization. All treated patients continue to remain
MRSA-negative at one month post-treatment. Microbiological assessments were
conducted via polymerase chain reaction (PCR) assays before and after
disinfection. No adverse events were noted in any patient.
    "Staphylococcus aureus, once a relatively innocuous microbe, has now
mutated into an extremely dangerous pathogen, in some cases demonstrating
resistance to all known antibiotics," said Carolyn Cross, Ondine Biopharma's
CEO and President. "Recent epidemiological surveys show that the prevalence of
invasive MRSA infections in the US has doubled over the past 5 years, and the
bacterium now causes more deaths in the US than AIDS. One in 20 will die of
this infection. MRSA often colonizes the lower portion of the nose, from where
it can be easily transmitted to patients, hospital visitors and healthcare
workers. Disinfection of the nose in MRSA carriers is a key step in reducing
the rate of these hospital-acquired infections. Our photodisinfection system
will enable clinicians in Canada and the EU to provide a safe, effective,
non-antibiotic alternative for nares disinfection, and does not encourage the
resistance generation that is a hallmark of antibiotic therapy."
    The Company's first photodisinfection product, Periowave(TM) has received
regulatory clearance for several oral and nasal disinfection indications in
Canada and the European Union. The nasal decolonization product is currently
being optimized to improve efficacy, ease of clinical use and market
acceptance prior to wide scale launch.

    About Photodisinfection

    Ondine has developed photodisinfection technologies that utilize
low-intensity lasers and wavelength-specific, light-activated photosensitive
compounds to target and destroy microbial pathogens and thereby reduce
symptoms of disease. The Company's photodisinfection system is currently
approved in Canada for nasal eradication of pathogenic bacteria such as MRSA
and for oral treatment of periodontitis, gingivitis, peri-implantitis,
peri-mucositis and endodontics. The system is also approved in the European
Union for nasal eradication of MRSA, and for treatment of periodontitis,
endodontics and peri-implantitis.

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com.

For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com; Irma
Gomez-Dib, Media & Investors Relations, FD International, (212) 850-5761,
Irma.gomez.dib@fd.com; Nominated Adviser, Neil Johnson, Ryan Gaffney,
Canaccord Adams Ltd, +44(0)20 7050 6500

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890